About: Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Margaretha Persson et al published June 2007 in Arteriosclerosis, Thrombosis, and Vascular Biology

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2007 (uk) im Juni 2007 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Margaretha Persson et al published June 2007 in Arteriosclerosis, Thrombosis, and Vascular Biology (en)
publication date	wds:Q57563944-5B1E7688-8523-428B-AB34-BB8960137DAF
publication date	2007-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57563944-43200A79-E5E4-45F0-A8AD-0ED430ECB406
language of work or name	English
author name string	wds:Q57563944-32BFDDB4-BC16-46A3-A1C5-8BE5310931B1 wds:Q57563944-C56720C3-E690-4165-8D99-9048F5742CC2 wds:Q57563944-F741660F-7A9E-4B5C-83F5-78BFE4FF8A3B
author name string	Bo Hedblad Göran Berglund Jeanenne J. Nelson
rdfs:label	Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (en) Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (nl)
skos:prefLabel	Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (en) Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (nl)
name	Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (en) Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (nl)
author	wds:Q57563944-D7CCE446-2C01-4ED0-91B3-AB101F0EE2BE
author	Margaretha Persson
title	wds:Q57563944-25B59E8D-E575-4A40-83BD-E1A8C334C49E
title	Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects (en)
page(s)	wds:Q57563944-AA6EF15B-F240-4053-AE92-5BEEC2BF1FE1
page(s)	1411-1416
instance of	wds:Q57563944-BB0F1D48-8F21-4E66-A94C-6B35010BBB7E
instance of	scholarly article
main subject	wds:Q57563944-38FFFEA1-B091-4C3A-88C4-65C031C17D05 wds:Q57563944-67EF8DAE-CEED-4A25-8E49-2B2079CE00EE
main subject	metabolic syndrome blood circulation
PubMed ID	wds:Q57563944-144D41C9-04A3-41D5-8194-770AA3F44048
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17431184
PubMed ID	17431184
published in	wds:Q57563944-5D92D66E-B219-4B95-A50E-A6E3481A0919
published in	Arteriosclerosis, Thrombosis, and Vascular Biology
issue	wds:Q57563944-603D2BEB-D14E-4332-9AD6-496B7E43260B
volume	wds:Q57563944-C278B3FE-5CA2-48D8-B079-FECDEFEDC8EA
issue	6
volume	27
DOI	wds:Q57563944-14494DD4-95ED-4FE1-BA6A-AF716FD19870
DOI	http://dx.doi.org/10.1161/ATVBAHA.107.142679
DOI	10.1161/ATVBAHA.107.142679
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57563944
is cites work of	2-Aminoadipic acid is a biomarker for diabetes risk Metabolite profiles and the risk of developing diabetes Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction Novel and conventional biomarkers for prediction of incident cardiovascular events in the community Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study Food patterns, inflammation markers and incidence of cardiovascular disease: the Malmö Diet and Cancer study Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study Developing and assessing cardiovascular biomarkers Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes Copeptin is an independent predictor of diabetic heart disease and death Plasma copeptin and the risk of diabetes mellitus A diabetes-predictive amino acid score and future cardiovascular disease Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study Metabolic syndrome: nature, therapeutic solutions and options Cardiovascular Disease in Women: Clinical Perspectives Plasma lipid composition and risk of developing cardiovascular disease Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction Diabetes mellitus and elevated copeptin levels in middle age predict low cognitive speed after long-term follow-up Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker Amino Acid Signatures to Evaluate the Beneficial Effects of Weight Loss Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population The tyranny of the averages and the indiscriminate use of risk factors in public health: The case of coronary heart disease. Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. Dimethylglycine Deficiency and the Development of Diabetes. New circulating biomarkers for predicting cardiovascular death in healthy population. Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women Chronic Diseases and Lifestyle Biomarkers Identification by Metabolomics. Cystatin C Is Not Causally Related to Coronary Artery Disease A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses Plasma copeptin as a predictor of kidney disease. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. C-reactive protein, established risk factors and social inequalities in cardiovascular disease - the significance of absolute versus relative measures of disease Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software